These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 29900067)

  • 41. FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer.
    Guan Y; Kraus SG; Quaney MJ; Daniels MA; Mitchem JB; Teixeiro E
    Front Oncol; 2020; 10():586. PubMed ID: 32391270
    [No Abstract]   [Full Text] [Related]  

  • 42. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD3
    Karjula T; Elomaa H; Niskakangas A; Mustonen O; Puro I; Kuopio T; Ahtiainen M; Mecklin JP; Seppälä TT; Wirta EV; Sihvo E; Väyrynen JP; Yannopoulos F; Helminen O
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
    Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
    Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
    [TBL] [Abstract][Full Text] [Related]  

  • 45. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
    Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
    J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
    Liu SS; Yang YZ; Jiang C; Quan Q; Xie QK; Wang XP; He WZ; Rong YM; Chen P; Yang Q; Yang L; Zhang B; Xia XJ; Kong PF; Xia LP
    J Transl Med; 2018 Jul; 16(1):195. PubMed ID: 30005666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of immune checkpoint blockade on antigen-specific CD8
    Ogando-Rivas E; Castillo P; Jones N; Trivedi V; Drake J; Dechkovskaia A; Candelario KM; Yang C; Mitchell DA
    Microbiol Immunol; 2022 May; 66(5):201-211. PubMed ID: 35150167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Immunotherapy Targeting Tumor-Associated Carbohydrate Antigens in Deficient Mismatch Repair Colorectal Cancer].
    Matsumoto T; Okayama H; Nakano H; Ito M; Nakajima S; Saito M; Saze Z; Momma T; Mimura K; Kono K
    Gan To Kagaku Ryoho; 2021 Oct; 48(10):1275-1277. PubMed ID: 34657062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
    Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
    Front Immunol; 2019; 10():2936. PubMed ID: 31921188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
    Shi L; Chen L; Wu C; Zhu Y; Xu B; Zheng X; Sun M; Wen W; Dai X; Yang M; Lv Q; Lu B; Jiang J
    Clin Cancer Res; 2016 Mar; 22(5):1173-1184. PubMed ID: 26933175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells
    Pedroza-Gonzalez A; Zhou G; Singh SP; Boor PP; Pan Q; Grunhagen D; de Jonge J; Tran TK; Verhoef C; IJzermans JN; Janssen H; Biermann K; Kwekkeboom J; Sprengers D
    Oncoimmunology; 2015 Dec; 4(12):e1051297. PubMed ID: 26587321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8
    Ascione A; Arenaccio C; Mallano A; Flego M; Gellini M; Andreotti M; Fenwick C; Pantaleo G; Vella S; Federico M
    BMC Biotechnol; 2019 Oct; 19(1):67. PubMed ID: 31623599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ACKR4 in Tumor Cells Regulates Dendritic Cell Migration to Tumor-Draining Lymph Nodes and T-Cell Priming.
    Wangmo D; Premsrirut PK; Yuan C; Morris WS; Zhao X; Subramanian S
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
    Narayanan S; Kawaguchi T; Yan L; Peng X; Qi Q; Takabe K
    Ann Surg Oncol; 2018 Aug; 25(8):2323-2331. PubMed ID: 29770915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Astragalus polysaccharide ameliorates CD8
    Li Q; Zhang C; Xu G; Shang X; Nan X; Li Y; Liu J; Hong Y; Wang Q; Peng G
    Biomed Pharmacother; 2024 Feb; 171():116172. PubMed ID: 38278025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of Immune Landscape Reveals Prognostic Significance of Cytotoxic CD4
    Qi J; Liu X; Yan P; He S; Lin Y; Huang Z; Zhang S; Xie S; Li Y; Lu X; Wu Y; Zhou Y; Yuan J; Cai T; Zheng X; Ding Y; Yang W
    Front Oncol; 2021; 11():724232. PubMed ID: 34631551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
    Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
    Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics.
    Jones D; Guan JJ; Calagua C; Hansel DE; Epstein JI; Ye H
    Hum Pathol; 2019 Dec; 94():58-63. PubMed ID: 31666198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.